Bal Pharma Limited

Equities

BALPHARMA

INE083D01012

Pharmaceuticals

Market Closed - Bombay S.E. 03:30:51 12/06/2024 pm IST 5-day change 1st Jan Change
120.6 INR -0.17% Intraday chart for Bal Pharma Limited +14.97% +19.95%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Bal Pharma Limited Recommends Dividend CI
Bal Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
Bal Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Bal Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Bal Pharma Limited Approves Dividend CI
Bal Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Bal Pharma Limited Appoints Abdul Basith as Company Secretary and Compliance Officer CI
Bal Pharma Limited Appoints Nicola Neeladri as Additional Director CI
Bal Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Bal Pharma Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023 CI
Bal Pharma Limited Recommends Dividend CI
Bal Pharma Limited Announces Resignation of Mrs.Preeti Singh as Company Secretary CI
Acuite Keeps BBB- Rating on Bal Pharma's Bank Loans; Outlook Stable MT
Bal Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Bal Pharma CFO Resigns MT
Bal Pharma Limited Announces Resignation of Mr. G. Rengarajan as Chief Financial Officer CI
Bal Pharma Limited Reports Earnings Results for the Half Year Ended September 30, 2022 CI
Bal Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Bal Pharma Limited Declares Dividend CI
Bal Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Bal Pharma Limited Appoints Kotian Chittananda Damodar as Additional Director (Non Independent) CI
Bal Pharma Limited Recommends Dividend CI
Acuite Upgrades Rating on Bal Pharma's Fund-Based Financing to BBB-; Lowers Outlook to Stable MT
Bal Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021 CI
ICRA Maintains BB+ Rating on Bal Pharma's Long-Term Bank Financing; Raises Outlook to Positive MT
Chart Bal Pharma Limited
More charts
Bal Pharma Limited is a pharmaceutical company, which is engaged in manufacturing and selling of pharmaceutical products. The Company is engaged in the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients (API). It is specialized in prescription drugs, generic & OTC products, intravenous infusion, and bulk actives. The Company offers range of APIs includes antihistamine, platelet inhibitor, anti-diabetic, anti-convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, acne treatment, and others. It also offers range of formulations products covering dosage forms-tablets, capsules, syrups, suspensions, IV infusions, ophthalmic, creams and ointments to various semi-regulated markets. The API products are being exported to Japan, Australia, Spain, the United Kingdom, Canada, Nigeria, Iceland, Slovenia, Romania, Brazil, Pakistan, Germany, South Africa, Serbia, Taiwan, Malaysia, Thailand, among others.
More about the company
1st Jan change Capi.
+19.95% 2.27Cr
+48.73% 78TCr
+41.76% 63TCr
+19.97% 33TCr
+6.91% 30TCr
+17.60% 24TCr
-0.41% 22TCr
+11.54% 21TCr
+4.35% 16TCr
-3.87% 16TCr
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. BALPHARMA Stock
  4. News Bal Pharma Limited
  5. Bal Pharma : ICRA Raises Rating on Bal Pharma's Fund-Based Financing, Term Loan to BB+; Keeps Stable Outlook